1. Home
  2. TII vs IPHA Comparison

TII vs IPHA Comparison

Compare TII & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Titan Mining Corporation

TII

Titan Mining Corporation

HOLD

Current Price

$1.90

Market Cap

198.5M

Sector

N/A

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.50

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TII
IPHA
Founded
2012
1999
Country
Canada
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.5M
165.3M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
TII
IPHA
Price
$1.90
$1.50
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$6.50
★ $6.67
AVG Volume (30 Days)
★ 230.3K
33.5K
Earning Date
11-13-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.91
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
$25.66
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$1.17
52 Week High
$5.65
$2.71

Technical Indicators

Market Signals
Indicator
TII
IPHA
Relative Strength Index (RSI) 30.87 41.16
Support Level $1.89 $1.36
Resistance Level $2.47 $1.57
Average True Range (ATR) 0.15 0.08
MACD -0.01 0.02
Stochastic Oscillator 10.37 33.33

Price Performance

Historical Comparison
TII
IPHA

About TII Titan Mining Corporation

Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: